GlassScriptPhysician profile
Kristina M Atkinson
NPI 1265703524
$3,495.17
in general payments reported to CMS, 2019-2025
19 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2022: $522 · 2023: $1,387 · 2024: $958 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,427.02 | 2022-2025 | Enhertu, Datroway |
| Seagen INC. | $490.55 | 2021-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $407.86 | 2022-2025 | Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $296.36 | 2021-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $192.26 | 2022-2024 | |
| Stemline Therapeutics INC. | $169.79 | 2023-2025 | Orserdu |
| Lilly USA, LLC | $113.86 | 2023-2024 | Verzenio, Retevmo |
| Genentech, INC. | $110.04 | 2024-2025 | Itovebi, Tecentriq |
| Myriad Genetic Laboratories, INC. | $42.60 | 2022-2024 | Myrisk |
| Genentech USA, INC. | $40.30 | 2023-2024 | Phesgo, Tecentriq |
| Genmab U.S., INC. | $37.53 | 2023-2025 | Tivdak |
| Eisai INC. | $31.09 | 2025 | |
| Incyte Corporation | $29.96 | 2022 | |
| Abbvie INC. | $28.46 | 2025 | |
| Tersera Therapeutics LLC | $20.90 | 2023 | Zoladex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $14.67 | 2024 | |
| Gilead Sciences, INC. | $14.65 | 2024 | |
| Legend Biotech USA INC. | $14.47 | 2025 | Carvykti |
| Pfizer INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.